CD4 and systemic sclerosis: Findings revealed that SSc-derived ADSCs maintained their immunomodulatory effect, downregulating CD25 and HLA-DR expression while upregulating CD69 on both CD4+ and CD8+ T cells, similar to healthy donor-derived ADSCs.